Clinical Trial
Published on 18 Feb 2021
Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors
in Translational Pharmacology
Frontiers in Pharmacology
doi 10.3389/fphar.2021.636324
- 3,443 views
- 3 citations
